American Heart Journal
Volume 148, Issue 6 , Pages 931-936 , December 2004

The continuing importance of prior stroke in STEMI patients

  • Michael A. Sloan, MD, MS, FACC

      Affiliations

    • Department of Neurological Sciences, Rush University Medical Center, 1725 W. , Harrison, Suite 1106, Chicago, IL, USA 60612
    • Corresponding Author InformationPhone 312-942-4500, FAX 312-563-3495,

References 

  1. Sloan MA, Gore JM. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol. 1992;69:21A–38A
  2. Sloan MA. Neurologic complications of thrombolytic therapy. In:  Biller J editors. Iatrogenic Neurology. Boston: Butterworth Heinemann; 1997;p. 335–378
  3. Fibrinolytic Therapy Trialists (FTT) Collaborative Group . Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311–322
  4. ISIS-2 (Second International Study of Infarct Survival) . Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349–360
  5. Gore JM, Sloan M, Price TR, et al.  TIMI Investigators   Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study: Thrombolysis in Myocardial Infarction, Phase II, Pilot and Clinical Trial. Circulation. 1991;83:448–459
  6. Sloan MA, Price TR, Terrin ML, et al.  TIMI Investigators   Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II Pilot and Randomized Trial combined experience. Stroke. 1997;28:1107–1114
  7. Gore JM, Granger CB, Simoons ML, et al.  GUSTO-I Investigators   Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial. Circulation. 1995;92:2811–2818
  8. Maggioni AP, Franzosi MG, Farnia ML, et al.  GISSI Group   Cerebrovascular events after myocardial infarction: Analysis of the GISSI trial. Br Med J. 1991;302:1428–1431
  9. Tanne D, Goldbourt U, Zion M, et al.  SPRINT Study Group   Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. Stroke. 1993;24:1490–1495
  10. Bodenheimer MM, Sauer D, Shareif B, et al.  Relation between myocardial infarction location and stroke. J Am Coll Cardiol. 1994;24:61–66
  11. Mahaffey KW, Granger CB, Sloan MA, et al.  GUSTO-I Investigators   Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I. Circulation. 1998;97:757–764
  12. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) . Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;i:397–402
  13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico . GISSI-2: A factorial randomized trial alteplase versus streptokinase, and heparin versus no heparin among 12,490 patients with myocardial infarction. Lancet. 1990;336:65–71
  14. International Study Group . In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized alteplase and streptokinase with or without heparin. Lancet. 1990;336:71–75
  15. de Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors. J Am Coll Cardiol. 1992;19:289–294
  16. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group . ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarctions. Lancet. 1992;339:753–770
  17. EMERAS (Estudio Multricentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group . Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767–772
  18. The Global Use of Strategies to Open Occluded Coronaries (GUSTO) IIa Investigators . Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631–1637
  19. International Joint Efficacy Comparison of Thrombolytics . Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet. 1995;346:329–336
  20. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators . Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet. 2001;358:1855–1863
  21. Wilcox RG, Olsson CG, Skene AM, et al.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;ii:525–530
  22. O'Connor CM, Califf RM, Massey EW, et al.  Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long term outcome. J Am Coll Cardiol. 1990;16:533–540
  23. Kase CS, Pessin MS, Zivin JA, et al.  Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am J Med. 1992;92:384–392
  24. Longstreth WT, Litwin PE, Weaver WD  MITI Project Group . Myocardial infarction, thrombolytic therapy, and stroke: A community study. Stroke. 1993;24:587–590
  25. LATE Study Group . Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759–766
  26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators . A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118–1123
  27. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators . A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med. 1997;337:1124–1130
  28. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators . Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716–722
  29. The InTIME-II Investigators . Intravenous NPA for the treatment of infracting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J. 2000;21:2005–2013
  30. The assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  31. The GUSTO-V Investigators . Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIB/IIIa inhibition: The GUSTO-V randomized trial. Lancet. 2001;357:1905–1914
  32. Gurwitz JH, Gore JM, Goldberg RJ, et al.  Participants in the National Registry of Myocardial Infarction 2   Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 1998;129:597–604
  33. Brass LM, Lichtman JH, Wang Y, et al.  Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project. Stroke. 2000;31:1802–1811
  34. Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis. Lancet. 2000;356:449–454
  35. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001;286:442–449
  36. Granger CB, Hirsh J, Califf RM, et al.  Activated partial thromboplastin time and outcome after thrombolytic therapy for acute thrombolytic therapy: Results from the GUSTO-I trial. Circulation. 1996;93:870–878
  37. Giugliano RP, McCabe CH, Antman EM, et al.  Lower dose heparin is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001;141:742–750
  38. Loh E, St. John Sutton M, Wuh CC-C, et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251–257
  39. Simoons ML, Maggioni AP, Knatterud G, et al.  Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet. 1993;342:1523–1528
  40. Selker HP, Beshansky JR, Schmid CH, et al.  Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI). Circulation. 1994;90:1657–1661
  41. Sloan MA, Giugliano RP, Thompson SL, et al.  Prediction of intracranial hemorrhage in the InTIME-II trial. J Am Coll Cardiol. 2001;37(Suppl. A):372A
  42. Kandzari DE, Granger CB, Simoons ML, et al.  GUSTO-1 Investigators   Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-1 Trial). Am J Cardiol. 2004;93:458–461
  43. AIMS Trial Study Group . Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet. 1988;i:545–549
  44. Tung CY, Granger CB, Sloan MA, et al.  GUSTO-I Investigators   Effects of stroke on medical resource use and costs in acute myocardial infarction. Circulation. 1999;99:370–376
  45. Tanne D, Gottlieb S, Hod H, et al.  Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) and Israeli Thrombolytic Survey Groups   Incidence and mortality from early stroke associated with acute myocardial infarction in the prethrombolytic and thrombolytic eras. J Am Coll Cardiol. 1997;30:1484–1490
  46. Tanne D, Yaari S, Goldbourt U. Risk profile and prediction of long-term ischemic stroke mortality: A 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation. 1998;98:1365–1371
  47. Tanne D, Gottlieb S, Caspi A, et al.  Israeli Thrombolytic National Survey Group   Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era. Arch Intern Med. 1998;158:601–606
  48. Reicher-Reiss H, Jonas M, Tanne D, et al.  Benzafibrate Infarction Prevention (BIP) Study Group   Prognostic significance of cerebrovascular disease in 11,526 chronic coronary artery disease patients. Am J Cardiol. 1998;82:1532–1535
  49. Cotter G, Cannon CP, McCabe CH, et al.  OPUS-TIMI 16 Investigators   Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcomes in patients with acute coronary syndromes: Are we doing enough?. Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. An Heart J. 2003;145:622–627
  50. Ryan TJ, Anderson JL, Antman EM, et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28:1328–1428
  51. Wallentin L, Armstrong P, Granger C, van de Werf F  ASSENT-III PLUS Investigators . Assessment of the safety and efficacy of a new thrombolytic regimen in the pre-hospital setting (ASSENT-III PLUS). Circulation. 2002;106(23):2986a
  52. Wienbergen H, Schiele R, Gitt AK, et al.  MIR and MITRA Study Groups   Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. Am J Cardiol. 2001;87:782–785
  53. Weaver WD, Simes RJ, Betriu A, et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA. 1997;278:2093–2098
  54. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  55. Cooper HA, Domanski MJ, Rosenberg Y, et al. and the MAGIC Trial Investigators: Acute ST-segment elevation myocardial infarction and prior stroke – An analysis from the Magnesium in Coronaries (MAGIC) trial. Am Heart J 2004;xx:yyy-yyy
  56. Morrow DA, Antman EA, Charlesworth A, et al.  TIMI Risk Score for ST-elevation myocardial infarction: A convenient, bedside clinical score for risk assessment at presentation. An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy. Cir-culation. 2000;102:2031–2037
  57. Morrow DA, Antman EA, Parsons L, et al.  Application of the TIMI Risk Score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286:1356–1359
  58. The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Investigators . Effects of long-term moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001;37:475–484
  59. van Es RF, Jonker JJC, Verheught FWA, et al.  Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group   Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet. 2002;360:109–113
  60. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. New Engl J Med. 2002;347:969–974

PII: S0002-8703(04)00403-X

doi: 10.1016/j.ahj.2004.06.010

American Heart Journal
Volume 148, Issue 6 , Pages 931-936 , December 2004

Article Tools